Rchr
J-GLOBAL ID：202001008565179672
Update date: Sep. 25, 2024
Sakai Daisuke
Sakai Daisuke
Affiliation and department：
Research theme for competitive and other funds (4)：
- 2018 - 2021 Realization of precision medicine for cancer chemotherapy
- 2018 - 2021 Elucidation and application of early brain metastasis mechanism by Warburg regulator MPC
- 2016 - 2018 New development of epigenome drug discovery to realize oncogene selectivity
- 2014 - 2016 Identification of new chemical compound to induce pancreatic beta-cells
Papers (151)：
-
Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, et al. Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902). International journal of clinical oncology. 2024. 29. 2. 134-141
-
Kuniko Sunami, Yoichi Naito, Yusuke Saigusa, Toraji Amano, Daisuke Ennishi, Mitsuho Imai, Hidenori Kage, Masashi Kanai, Hirotsugu Kenmotsu, Keigo Komine, et al. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA oncology. 2023
-
Yutaka Kimura, Hisato Kawakami, Shigeyuki Tamura, Kazumasa Fujitani, Jin Matsuyama, Hiroshi Imamura, Shohei Iijima, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, et al. Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2023. 26. 5. 788-797
-
Hiroki Yukami, Hisato Kawakami, Toshifumi Yamaguchi, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Masahiro Goto, Taroh Satoh. Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106). International journal of clinical oncology. 2023. 28. 9. 1176-1182
-
Chiaki Inagaki, Hisato Kawakami, Daichi Maeda, Daisuke Sakai, Shinya Urakawa, Kentaro Nishida, Toshihiro Kudo, Yuichiro Doki, Hidetoshi Eguchi, Hisashi Wada, et al. The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. Scientific reports. 2023. 13. 1. 5652-5652
ｍore...
MISC (68)：
-
王谷 英達, 畑毛 一枝, 坂井 大介, 佐藤 太郎, 伊村 慶紀, 中井 隆彰, 名井 陽, 岡田 誠司. ゲノム医療時代の骨・軟部腫瘍医 肉腫診療におけるがんゲノム医療の実際. 日本整形外科学会雑誌. 2022. 96. 6. S1284-S1284
-
Atsushi Yasuda, Jin Matsuyama, Tetsuji Terazawa, Masahiro Goto, Ryohei Kawabata, Shunji Endo, Motohiro Imano, Shoichiro Fujita, Yusuke Akamaru, Hirokazu Taniguchi, et al. A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601). JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 3
-
村地 康, 坂井 大介, 小関 準, 稲垣 千晶, 西田 尚弘, 山口 敏史, 佐藤 太郎. レゴラフェニブで治療した進行・再発結腸直腸癌患者におけるサルコペニアの影響. 日本癌治療学会学術集会抄録集. 2020. 58回. P-484
-
Masashi Hirota, Shigeyuki Tamura, Hirokazu Taniguchi, Atsushi Takeno, Hiroshi Imamura, Junya Fujita, Jin Matsuyama, Yutaka Kimura, Junji Kawada, Motohiro Hirao, et al. A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
-
Jin Matsuyama, Hisato Kawakami, Kazumasa Fujitani, Yusuke Akamaru, Shigeyuki Tamura, Shunji Endo, Yutaka Kimura, Youichi Makari, Takao Tamura, Naotoshi Sugimoto, et al. Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naive advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
ｍore...
Return to Previous Page
